Loy R - Search Results

1

Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.

Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR Jr, Thal L, Aisen PS; Alzheimer's Disease Cooperative Study Group. Tariot PN, et al. Among authors: loy r. Arch Gen Psychiatry. 2011 Aug;68(8):853-61. doi: 10.1001/archgenpsychiatry.2011.72. Arch Gen Psychiatry. 2011. PMID: 21810649 Free PMC article. Clinical Trial.

2

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales.

Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S. Tariot PN, et al. Among authors: loy r. Adv Drug Deliv Rev. 2002 Dec 7;54(12):1567-77. doi: 10.1016/s0169-409x(02)00153-9. Adv Drug Deliv Rev. 2002. PMID: 12453674 Review.

3

Neuroprotective properties of valproate: potential benefit for AD and tauopathies.

Loy R, Tariot PN. Loy R, et al. J Mol Neurosci. 2002 Dec;19(3):303-7. doi: 10.1385/jmn:19:3:301. J Mol Neurosci. 2002. PMID: 12540056

4

Pharmacologic therapy for behavioral symptoms of Alzheimer's disease.

Tariot PN, Ryan JM, Porsteinsson AP, Loy R, Schneider LS. Tariot PN, et al. Among authors: loy r. Clin Geriatr Med. 2001 May;17(2):359-76. doi: 10.1016/s0749-0690(05)70073-2. Clin Geriatr Med. 2001. PMID: 11375140 Review.

5

Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium.

Mhyre TR, Loy R, Tariot PN, Profenno LA, Maguire-Zeiss KA, Zhang D, Coleman PD, Federoff HJ. Mhyre TR, et al. Among authors: loy r. Neurobiol Aging. 2008 Nov;29(11):1631-43. doi: 10.1016/j.neurobiolaging.2007.04.004. Epub 2007 May 22. Neurobiol Aging. 2008. PMID: 17521776 Free PMC article. Clinical Trial.

6

Physiologic and neuroendocrine responses to intravenous naloxone in subjects with Alzheimer's disease and age-matched controls.

Tariot PN, Upadhyaya A, Sunderland T, Cox C, Cohen RM, Murphy DL, Loy R. Tariot PN, et al. Among authors: loy r. Biol Psychiatry. 1999 Aug 1;46(3):412-9. doi: 10.1016/s0006-3223(98)00329-1. Biol Psychiatry. 1999. PMID: 10435208 Free article. Clinical Trial.

7

Impact of molecular medicine on neuropsychiatry: the clinician's perspective.

Ryan JM, Loy R, Tariot PN. Ryan JM, et al. Among authors: loy r. Curr Psychiatry Rep. 2001 Oct;3(5):355-60. doi: 10.1007/s11920-996-0026-y. Curr Psychiatry Rep. 2001. PMID: 11559470 Review.

8

Increased levels of truncated nerve growth factor receptor in urine of mildly demented patients with Alzheimer's disease.

Lindner MD, Gordon DD, Miller JM, Tariot PN, McDaniel KD, Hamill RW, DiStefano PS, Loy R. Lindner MD, et al. Among authors: loy r. Arch Neurol. 1993 Oct;50(10):1054-60. doi: 10.1001/archneur.1993.00540100049013. Arch Neurol. 1993. PMID: 8215963

9

Localization of NGF receptors in normal and Alzheimer's basal forebrain with monoclonal antibodies against the truncated form of the receptor.

Loy R, Heyer D, Clagett-Dame M, DiStefano PS. Loy R, et al. J Neurosci Res. 1990 Dec;27(4):651-64. doi: 10.1002/jnr.490270426. J Neurosci Res. 1990. PMID: 1964180

10

Developmental regulation of human truncated nerve growth factor receptor.

DiStefano PS, Clagett-Dame M, Chelsea DM, Loy R. DiStefano PS, et al. Among authors: loy r. Ann Neurol. 1991 Jan;29(1):13-20. doi: 10.1002/ana.410290105. Ann Neurol. 1991. PMID: 1847613

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

123 results

Search Page

Filters